Orchid Pharma Limited (BOM:524372)
810.85
+0.85 (0.10%)
At close: Apr 23, 2025
Orchid Pharma Revenue
Orchid Pharma had revenue of 2.17B INR in the quarter ending December 31, 2024, a decrease of -1.47%. This brings the company's revenue in the last twelve months to 9.02B, up 11.01% year-over-year. In the fiscal year ending March 31, 2024, Orchid Pharma had annual revenue of 8.19B with 23.05% growth.
Revenue (ttm)
9.02B
Revenue Growth
+11.01%
P/S Ratio
4.56
Revenue / Employee
10.35M
Employees
871
Market Cap
41.14B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 8.19B | 1.53B | 23.05% |
Mar 31, 2023 | 6.66B | 1.06B | 19.00% |
Mar 31, 2022 | 5.60B | 1.09B | 24.33% |
Mar 31, 2021 | 4.50B | -337.41M | -6.97% |
Mar 31, 2020 | 4.84B | -1.16B | -19.36% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,627.08B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,409.52B |
Infosys | 1,647.16B |
Bajaj Finance | 358.05B |
Orchid Pharma News
- 2 months ago - Orchid Pharma shares surge 4.4% after successful USFDA inspection at Alathur API facility - Business Upturn
- 2 months ago - Orchid Pharma successfully completes USFDA inspection at Alathur API facility, secures EU GMP certification renewal - Business Upturn
- 2 months ago - Orchid Pharma shares drop over 14% as net profit falls 25.63% YoY to ₹22.45 crore in Q3 - Business Upturn
- 5 months ago - Orchid Pharma shares jump nearly 4% following strong Q2 FY25 results - Business Upturn
- 5 months ago - Orchid Pharma Q2 FY25 Results: Revenue jumps 12% to ₹222.7 crore, PAT up 26% YoY - Business Upturn